Catalog No.
DHJ42201
Expression system
Mammalian Cells
Species reactivity
Human
Host species
Human
Isotype
IgG1-kappa
Clonality
Monoclonal
Target
BR3, TNFRSF13C, BAFF receptor, BLyS receptor 3, Tumor necrosis factor receptor superfamily member 13C, CD268, B-cell-activating factor receptor, BAFFR, BAFF-R
Concentration
1.1 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
Q96RJ3
Applications
Research Grade Biosimilar
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names
VAY-736, CAS: 1929549-92-7
Clone ID
Ianalumab
Treatment of primary Sjögren's syndrome with ianalumab (VAY736) targeting B cells by BAFF receptor blockade coupled with enhanced, antibody-dependent cellular cytotoxicity, PMID: 30826774
Sjögren's syndrome: Old and new therapeutic targets, PMID: 31831255
Ianalumab (VAY736) in primary Sjögren's syndrome: assessing disease activity using multi-modal ultrasound, PMID: 33095139
Targeted therapies in systemic sclerosis, myositis, antiphospholipid syndrome, and Sjögren's syndrome, PMID: 32067925
Biologics in the treatment of Sjogren's syndrome, systemic lupus erythematosus, and lupus nephritis, PMID: 33002950
[Sjögren's syndrome: from diagnosis to treatment], PMID: 33689243
Combination Therapy for Treating Advanced Drug-Resistant Acute Lymphoblastic Leukemia, PMID: 31138521
Anti-BAFF-R antibody VAY-736 demonstrates promising preclinical activity in CLL and enhances effectiveness of ibrutinib, PMID: 30737226
Infections in Sjögren's disease: a clinical concern or not?, PMID:39661562
Safety and Efficacy of Ianalumab in Patients With Sjögren's Disease: 52-Week Results From a Randomized, Placebo-Controlled, Phase 2b Dose-Ranging Study., PMID:39557617
Autoimmune Hemolytic Anemias: Challenges in Diagnosis and Therapy., PMID:39371250
Anti-B-Cell-Activating Factor (BAFF) Therapy: A Novel Addition to Autoimmune Disease Management and Potential for Immunomodulatory Therapy in Warm Autoimmune Hemolytic Anemia., PMID:39062171
[Focus on Sjögren's syndrome - Diagnosis and treatment]., PMID:38781999
The role of BAFF and BAFF-R inhibitors in the treatment of immune thrombocytopenia; a focused review., PMID:38460303
Antibody based therapeutics for autoimmune hemolytic anemia., PMID:37874225
Ianalumab in Sjögren's syndrome: what can we learn from lupus trials? - Authors' reply., PMID:36088946
Ianalumab in Sjögren's syndrome: what can we learn from lupus trials?, PMID:36088945
Advancing Biologic Therapy for Refractory Autoimmune Hepatitis., PMID:35147819
Safety and efficacy of subcutaneous ianalumab (VAY736) in patients with primary Sjögren's syndrome: a randomised, double-blind, placebo-controlled, phase 2b dose-finding trial., PMID:34861168
Targeted Therapy for Primary Sjögren's Syndrome: Where are We Now?, PMID:34731460
[Sjögren's syndrome: from diagnosis to treatment]., PMID:33689243
Ianalumab (VAY736) in primary Sjögren's syndrome: assessing disease activity using multi-modal ultrasound., PMID:33095139
Biologics in the treatment of Sjogren's syndrome, systemic lupus erythematosus, and lupus nephritis., PMID:33002950
Targeted therapies in systemic sclerosis, myositis, antiphospholipid syndrome, and Sjögren's syndrome., PMID:32067925
Sjögren's syndrome: Old and new therapeutic targets., PMID:31831255
Combination Therapy for Treating Advanced Drug-Resistant Acute Lymphoblastic Leukemia., PMID:31138521
Treatment of primary Sjögren's syndrome with ianalumab (VAY736) targeting B cells by BAFF receptor blockade coupled with enhanced, antibody-dependent cellular cytotoxicity., PMID:30826774
Anti-BAFF-R antibody VAY-736 demonstrates promising preclinical activity in CLL and enhances effectiveness of ibrutinib., PMID:30737226
For research use only. Not for human or drug use.
